BNC Korea
한국비엔씨 · 256840
Health Care Pharmaceuticals · KOSDAQ
Market cap US$148.2M (₩204.5B)
Overview
BNC Korea makes injectable dermal fillers, botulinum toxin treatments (the active ingredient in wrinkle-relaxing injections), collagen-based tissue supplements, and functional skincare products, all aimed at the medical aesthetics and dermatology market.
Its products are used by clinics and medical professionals, and it also distributes through cosmetics channels. The company spans medical devices, pharmaceuticals, and cosmetics within a single business, and is listed on KOSDAQ, South Korea's tech and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$58.7M
- FY2024US$64.7M
- FY2025US$69.5M
Operating profit
- FY2023US$4.4M
- FY2024US$7.8M
- FY2025US$1.2M
Net income
- FY2023US$18.9M
- FY2024US$9.6M
- FY2025US$1.5M
Key ratios (FY2025)
Why it matters
Its consolidated subsidiaries separately develop and distribute aesthetic medical devices as well as biotechnology research reagents and testing equipment, broadening the group's product scope beyond injectables.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?